Oral Ondansetron Offers Effective Symptomatic Bridging for Carcinoid Syndrome Refractory to Somatostatin Analogues

#2097

Introduction: Somatostatin analogues (SSA) are standard for symptomatic patients with neuroendocrine tumours (NETs). However, most patients experience tachyphylaxis, and limited options exist for this refractory carcinoid syndrome (RCS). Recently, ondansetron has been associated with reduction of bowel movement in a small series.

Aim(s): The aim of this analysis was to assess effectiveness of ondansetron for symptomatic treatment of RCS.

Materials and methods: We have analysed patients given oral ondansetron as bridging therapy for RCS. The dose was 2x8 mg for 5 days, followed by reduction to 1x8 mg in case of benefit.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Duan H, Haug A, Riss P, Selberherr A,

Keywords: carcinoid syndrome, ondansetron, 5-HT3 antagonist, neuroendocrine tumor, somatostatin, analogues,

To read the full abstract, please log into your ENETS Member account.